A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Conditions: Solid Tumors; Advanced Triple Negative Breast Cancer; Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer; Advanced Metastatic Castration-Resistant Prostate Cancer; Advanced Platinum-Resistant Ovarian Cancer
Interventions: Drug: TRX518; Drug: Cyclophosphamide; Drug: Avelumab
Sponsors: Leap Therapeutics, Inc.; Pfizer; Merck KGaA, Darmstadt, Germany
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 1, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments